Avidity Biosciences Inc (RNA)
28.96
+0.24
(+0.84%)
USD |
NASDAQ |
May 17, 11:59
Avidity Biosciences Cash from Financing (Quarterly): 389.44M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 389.44M |
December 31, 2023 | 31.89M |
September 30, 2023 | 0.04M |
June 30, 2023 | 38.97M |
March 31, 2023 | 22.96M |
December 31, 2022 | 243.65M |
September 30, 2022 | 39.62M |
June 30, 2022 | 38.78M |
March 31, 2022 | 24.11M |
December 31, 2021 | 20.71M |
September 30, 2021 | 155.17M |
Date | Value |
---|---|
June 30, 2021 | 0.413M |
March 31, 2021 | 0.017M |
December 31, 2020 | 0.45M |
September 30, 2020 | -1.346M |
June 30, 2020 | 271.61M |
March 31, 2020 | 1.323M |
December 31, 2019 | 71.82M |
September 30, 2019 | -0.712M |
June 30, 2019 | 14.30M |
March 31, 2019 | 3.822M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.346M
Minimum
Sep 2020
389.44M
Maximum
Mar 2024
68.16M
Average
23.54M
Median
Cash from Financing (Quarterly) Benchmarks
Catalyst Pharmaceuticals Inc | 141.05M |
Vertex Pharmaceuticals Inc | -357.50M |
Codexis Inc | 29.28M |
Sarepta Therapeutics Inc | 22.14M |
PTC Therapeutics Inc | 0.54M |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -70.38M |
Cash from Investing (Quarterly) | -32.75M |
Free Cash Flow | -143.80M |
Free Cash Flow Per Share (Quarterly) | -0.8175 |
Free Cash Flow to Equity (Quarterly) | -71.30M |
Free Cash Flow Yield | -6.43% |